港股異動丨貓眼娛樂(1896.HK)3日累計反彈超10% 2020年度電影票房突破200億
格隆匯12月31日丨近日影視娛樂股開始反彈,貓眼娛樂(1896.HK)3日累計升幅超10%,現報12.18港元,漲5%,總市值138.43億港元。貓眼專業版顯示,截至12月30日22時36分,2020年度電影票房突破200億元。另外,第51周(12月21日-12月27日),全國電影票房收入10.98億元人民幣,按周增長69.24%,是繼國慶檔之後,單週票房大盤再度突破10億元人民幣。2021年春節檔大片雲集,有望繼續拉昇觀眾觀影熱情,加速推進電影市場復甦,頭部影片相關製作企業有望受益。美銀證券曾估計貓眼盈利將在2021財年復甦,以反映疫情對電影行業的影響。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.